Want to see INM full AI Analyst Report?
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.58 - $2.50
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$4.84M
Enterprise Value-$2.17
Total Cash (Recent Filing)$5.20M
Total Debt (Recent Filing)$420.15K
Price to Earnings (P/E)―
Beta3.23
Next Earnings
Sep 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1142.54
Shares Outstanding3,314,063
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetVery low debt-to-equity (~0.4%) reduces refinancing and solvency risk, giving management structural financial flexibility. Over 2-6 months this supports funding clinical programs or absorbing integration costs without immediate pressure to raise dilutive equity, improving strategic optionality.
Merger Financing Materially Extends RunwayThe combined financings backing the Mentari reverse merger provide multi-year runway and capital to advance Phase 2a migraine programs. Structurally, secured clinical financing reduces near-term funding risk and permits execution of development milestones that can de-risk the pipeline and create long-term value.
R&D Progress: INM-901 Preclinical TranslatabilityConsistent anti-inflammatory effects across in vivo, ex vivo and human organoid systems strengthen translational confidence for INM-901. Durable scientific validation increases the likelihood of successful clinical translation and supports long-term pipeline value beyond short-term fluctuations.
Bears Say
High Cash Burn / Negative Cash FlowDeeply negative operating and free cash flow materially raise funding risk over the medium term. Structural cash burn implies the company will need continued financing to sustain R&D and operations, likely resulting in future dilution or onerous financing terms that can impair shareholder value.
Weak Profitability And Low Gross MarginA ~10% TTM gross margin and persistent negative EBITDA show the business lacks margin sustainability. Even with revenue growth, a structurally low margin profile limits operating leverage and the ability to reach durable profitability without significant cost structure changes or higher-margin revenue.
Major Dilution And Governance Shift From Reverse MergerThe reverse merger transfers near-total ownership and control to Mentari stakeholders, substantially diluting legacy InMed holders and shifting board/management. This structural ownership change can misalign incentives, reduce influence for existing investors, and concentrate decision-making risk.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.57 and its highest was $2.50 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $4.84M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is Sep 18, 2026 which is in 23 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on May 06, 2026. The company reported -$0.733 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 3,314,063 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.132%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses cannabinoid-based interventions for a variety of medical conditions, with a particular focus on dermatological and ocular disorders. Furthermore, InMed is involved in critical IND-enabling pharmacology and preclinical toxicology research. It is also pioneering IntegraSyn, an innovative integrated biosynthesis approach designed to produce pharmaceutical-grade cannabinoids efficiently. The company maintains a research partnership with BayMedica Inc. to collaborate on the formulation and assessment of novel cannabinoid therapeutics. Established in 1981, the company is headquartered in Vancouver, Canada. It operated under the name Cannabis Technologies Inc. before officially rebranding as InMed Pharmaceuticals Inc. in October 2014.
Technical Analysis
Galmed Pharmaceuticals
―
Collplant Holdings
―
Enveric Biosciences
―
Silo Pharma
―
Addex Therapeutics
―
Ownership Overview
60.53% Insiders
0.60% Other Institutional Investors
38.87% Public Companies and
Individual Investors